Melanin nanoparticles alleviate sepsis-induced myocardial injury by suppressing ferroptosis and inflammation
- Bioact Mater. 2022 Dec 27:24:313-321. doi: 10.1016/j.bioactmat.2022.12.026.
- 1. School of Medical Technology, Tianjin Medical University, Tianjin, 300203, China.
- 2. Key Laboratory of Emergency and Trauma of Ministry of Education, Hainan Medical University, Haikou, 571199, China.
- 3. Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China.
- 4. Department of Molecular Pharmacology, School of Medicine, Nankai University, Tianjin, 300071, China.
- 5. Tianjin Key Laboratory of General Surgery in Construction, Tianjin Union Medical Center, Tianjin, 300000, China.
- 6. Xinjiang Production and Construction Corps Hospital, Xinjiang, 830092, China.
Myocardial injury as one of the severe complications leads to the increasing morbidity and mortality in patients with sepsis. Recent studies reported that Reactive Oxygen Species (ROS)-mediated Ferroptosis plays a critical role in the development of heart diseases. Therefore, we hypothesized that anti-ferroptosis agent might be a novel potential therapeutic strategy for sepsis-induced cardiac injury. Herein, we demonstrated that a small biocompatible and MRI-visible melanin nanoparticles (MMPP) improves myocardial function by inhibiting ROS-related Ferroptosis signaling pathway. In LPS-induced murine sepsis model, after a single dose intravenously injection of MMPP treatment, MMPP markedly alleviated the myocardial injury including cardiac function and heart structure disorder through suppressing iron-accumulation induced Ferroptosis. In vitro, MMPP inhibited cardiomyocyte death by attenuating oxidative stress, inflammation and maintaining mitochondrial homeostasis. Collectively, our findings demonstrated that MMPP protected heart against sepsis-induced myocardial injury via inhibiting Ferroptosis and inflammation, which might be a novel therapeutic approach in future.
-
Cat. No.Product NameDescriptionTargetResearch Area
-